Clinical trials: Telangiectasia, Hereditary Hemorrhagic
Hereditary Haemorrhagic Telangiectasia
Iron Deficiency and Hereditary Haemorrhagic Telangiectasia
Managing iron deficiency is important for more than 1 billion individuals worldwide, to avoid blood transfusions, or excessive strain on vital organs that depend on iron-containing haemoglobin to deliver oxygen to the tissues.
- Trial name
- NCT01908543
- Testing
- Ferrous sulphate 200mg oral tablet
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- Imperial College London
Hemorrhagic Hereditary Telangiectasia
Efficacy and Safety of Bevacizumab for the Treatment Hemorrhagic Hereditary Telangiectasia (HHT) Associated With Severe Hepatic Vascular Malformations. Phase II Study
The efficacy of anti-VEGF treatments such as Bevacizumab in cases of HHT can be considered because of the molecular mechanisms implied in angiogenesis and HHT, as well as the mechanisms of action of this type of treatment.
- Trial name
- METAFORE (NCT00843440)
- Testing
- Bevacizumab
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Hospices Civils de Lyon
Hereditary Haemorrhagic Telangiectasia (HHT)
Quality of Life in Pediatric Participants With HHT
This observational study evaluates health-related quality of life (HR-QoL) in pediatric and young adult patients aged 2-25 years with Hereditary Hemorrhagic Telangiectasia (HHT).
- Trial name
- NCT07474428
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Ashley Nelson
Telangiectasia, Hereditary Hemorrhagic
Study of Endothelial Cells in Patients With Hereditary Haemorrhagic Telangiectasia
Hereditary Haemorrhagic Telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome) is an disease that leads to the development of dilated and fragile blood vessels.
- Trial name
- NCT00733629
- Where
- United Kingdom
- Sponsor
- Imperial College London
Hereditary Haemorrhagic Telangiectasia
Evaluation of Video-assisted Instructions of Nasal Self-packing in Patients with HHT
Inserting nasal self-packings is a secure method leaving patients more self-confident. We provide a video on https://www.youtube.com/watch?v=LaioLYfSJ-E demonstrating how to use nasal self-packings.
- Trial name
- NCT03841422
- Testing
- video-assisted nasal self-packing
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University Hospital, Essen
Hereditary Haemorrhagic Telangiectasia, Pulmonary Arteriovenous Malformation
Pulmonary Arteriovenous Malformations (PAVMs) in Hereditary Haemorrhagic Telangiectasia (HHT)
Computed tomography (CT) is the modality of choice to characterize pulmonary arteriovenous malformations (PAVMs) in patients with hereditary haemorrhagic telangiectasia (HHT).
- Conditions
- Hereditary Haemorrhagic Telangiectasia, Pulmonary Arteriovenous Malformation, Cerebral Disorder
- Trial name
- PAVM (NCT03940014)
- Testing
- Data collection from standard follow up
- Volunteers
- 170 people
- Sponsor
- Hospices Civils de Lyon
Telangiectasia, Hereditary Hemorrhagic, Rendu Osler Disease
Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease.
The recognized manifestations of HHT are all due to abnormalities in vascular structure. Epistaxis are spontaneous, very variable, may occur as often as several times every day, and are recurrent in 90% of patients and associated…
- Trial name
- EPICURE (NCT03954782)
- Testing
- Nintedanib 150 mg and 100 mg soft capsules
- Where
- 8 sites in France
- Volunteers
- 61 people
- Sponsor
- Hospices Civils de Lyon
Pulmonary Arteriovenous Malformations, Hereditary Hemorrhagic Telangiectasia
Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs
Pulmonary arteriovenous malformations (PAVMs) are a rare vascular condition affecting the lungs. PAVMs lead to low blood oxygen levels, yet are very well tolerated by patients.
- Trial name
- NCT02436213
- Testing
- Cardiopulmonary exercise test, Blood test
- Where
- United Kingdom
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Hereditary Hemorrhagic Telangiectasia
Body Donation in HHT
The possibility of body donation in hereditary hemorrhagic telangiectasia (HHT) means that human tissue samples with and without vascular malformations can be analyzed. The aim is to gain insights into the disease mechanism.
- Trial name
- NCT07826845
- Testing
- body donation in HHT
- Where
- Germany
- Volunteers
- 5 people
- Sponsor
- University Hospital, Essen
Hereditary Hemorrhagic Telangiectasia
Quality of Life in Patients With Hemorrhagic Telangiectasia
Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler's disease, is a genetic disorder that leads to abnormal blood vessel formations.
- Trial name
- NCT06261333
- Testing
- Questionnaires
- Where
- Germany
- Volunteers
- 250 people
- Sponsor
- University Hospital, Essen
Hereditary Haemorrhagic Telangiectasia
Hereditary Haemorrhagic Telangiectasia Flight Safety Study
Hereditary Haemorrhagic Telangiectasia (HHT) is a condition in which sufferers have abnormal blood vessels which makes them more likely to bleed than other people, particularly in the lungs, which results in low blood oxygen…
- Trial name
- Flying and HHT (NCT01590121)
- Testing
- Aeroplane flight in the past- no active intervention for study, Questionnaire
- Where
- United Kingdom
- Volunteers
- 156 people
- Sponsor
- Imperial College London
Hereditary Hemorrhagic Telangiectasia (HHT), Rendu Osler Disease
IV Bevacizumab Treatment of Patients With Hereditary Hemorrhagic Telangiectasia (HHT) or Rendu-Osler (RO) Disease: A Retrospective Analysis of French Cohort Data From 2009 to 2024
Rendu-Osler disease (RO), also known as Hereditary Haemorrhagic Telangiectasia (HHT), is an autosomal dominant genetic disorder. Its pathophysiology is associated with an imbalance in angiogenic balance.
- Trial name
- CoBé (NCT07772050)
- Testing
- Real World data study.
- Where
- France
- Volunteers
- 244 people
- Sponsor
- Hospices Civils de Lyon
Hereditary Hemorrhagic Telangiectasia
Prospective Descriptive Study of the Angiogenic T Cell Population in Subjects With Hereditary Hemorrhagic Telangiectasia (HHT)
Hereditary hemorrhagic telangiectasia (HHT) results from genetic deregulation of angiogenesis. It is characterized by mucocutaneous telangiectasia responsible for recurrent epistaxis affecting quality of life (anaemia, iron…
- Trial name
- TangRO (NCT03572556)
- Testing
- Blood samples, Epistaxis charts
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon
Hereditary Haemorrhagic Telangiectasia, PFO - Patent Foramen Ovale
Non-Invasive Detection of Pulmonary Right-to-Left Shunts Using the SONAS Ultrasound Device
The goal of this clinical trial is to learn how well the SONAS ultrasound device can detect right-to-left shunts of adults with hereditary hemorrhagic telangiectasia (HHT) who are already scheduled for a contrast bubble…
- Conditions
- Hereditary Haemorrhagic Telangiectasia, PFO - Patent Foramen Ovale, Pulmonary Arteriovenous Malformation
- Trial name
- SONAS (NCT07414446)
- Testing
- Transcranial Ultrasound Device
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- St. Antonius Hospital
Hereditary Hemorrhagic Telangiectasia
Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept
Hereditary hemorrhagic telangiectasia (HHT) is a hereditary vascular condition characterized by the development of abnormal connections between arteries and veins throughout the body, called vascular malformations.
- Trial name
- NCT01752049
- Testing
- Topical timolol maleate
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- Unity Health Toronto
Telangiectasia, Hereditary Hemorrhagic, Osler Rendu Disease
Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO)
Timolol is a nonselective β-blocker commonly used in the treatment of glaucoma. Recently it has been used topically for the treatment of superficial hemangiomas.
- Trial name
- TEMPO (NCT02484716)
- Testing
- Timolol nasal spray
- Where
- France
- Volunteers
- 58 people
- Sponsor
- Hospices Civils de Lyon
Hereditary Hemorrhagic Telangiectasia (HHT), Obstructive Sleep Apnea (OSA)
Prevalence of Obstructive Sleep Apnea in HHT and HHT-specific Challenges in OSA-therapy - a Retrospective Cohort Study
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular disorder (prevalence approx. 1:5,000-1:8,000) characterized by recurrent epistaxis, mucocutaneous telangiectasias and visceral vascular malformations.
- Trial name
- NCT07886632
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Essen
Hereditary Hemorrhagic Telangiectasia, Dental Diseases
Nationwide Awareness Campaign and Call for Dental Screening for HHT in Germany
HHT is a relative rare autosomal dominant inherited disorder of the fibrovascular tissue. Diagnosis of HHT is often delayed for decades (Pierucci 2012).
- Trial name
- NCT03549949
- Where
- Germany
- Volunteers
- 411 people, healthy volunteers welcome
- Sponsor
- University Hospital, Essen
Hereditary Hemorrhagic Telangiectasia, Epistaxis
Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia
Investigators will test the value of very low dose Pazopanib administered to patients with hereditary hemorrhagic telangiectasia for the reduction in the severity of nose bleeds in those with frequent and long duration bleeding…
- Trial name
- NCT03850730
- Testing
- Pazopanib
- Volunteers
- 30 people
- Sponsor
- Cure HHT
Telangiectasia, Hereditary Hemorrhagic, Epistaxis
North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
The purpose of the NOSE Study is to carefully examine the efficacy and safety of 3 nasal sprays (bevacizumab, estriol, and tranexamic acid), compared to placebo, for the treatment of HHT related nosebleeds.
- Trial name
- NOSE (NCT01408030)
- Testing
- Sterile saline, Bevacizumab, Estriol
- Where
- 6 sites in United States
- Volunteers
- 123 people
- Sponsor
- James Gossage